3 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCCHead and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, laryngeal disorder, laryngeal neoplasm, mouth disorder, neoplasm, otorhinolaryngologic disease, respiratory system disorder, respiratory tract neoplasm, squamous cell carcinomaActive, not recruitingPhase 2 / Phase 32026-05-08NCT06295731
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's SyndromePrimary Sjogrens DiseaseActive, not recruitingPhase 32026-04-16NCT06684847
A Study of Sasanlimab in People With Non-muscle Invasive Bladder CancerFemale Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorderActive, not recruitingPhase 32026-01-22NCT04165317